Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. ‘I actually started crying’
A new experimental pill, daraxonrasib, has shown significant promise in treating advanced pancreatic cancer by targeting a mutated protein that fuels tumor growth. In a study, patients taking the daily pill nearly doubled their survival time compared to those receiving chemotherapy, with fewer severe side effects. This development is being hailed as a major step forward for a disease with historically poor treatment outcomes, and the drug is expected to become a new standard of care. AI
IMPACT Potential to establish a new standard of care for a deadly cancer, improving patient outcomes.